Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2016

Gayvert KM, Dardenne E, Cheung C, Boland MR, Lorberbaum T, Wanjala J, et al. A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors. Cell Rep. 2016;15(11):2348-56.

Huong G, Olson LC, Rippis GE, Magro CM. An Index Case of Cutaneous Hodgkin Lymphoma and Review of the Literature. Am J Dermatopathol. 2016;38(10):739-43.

Lee SS, Tyler JK. Physiology: Stressed-out chromatin promotes longevity. Nature. 2016;534(7609):625-6.

Lee SY, T Kingham P, LaGratta MD, Jessurun J, Cherqui D, Jarnagin WR, et al. PET-avid hepatocellular adenomas: incidental findings associated with HNF1-α mutated lesions. HPB (Oxford). 2016;18(1):41-8.

Kumar B, Khaleghzadegan S, Mears B, Hatano K, Kudrolli TA, Chowdhury WH, et al. Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening. Oncotarget. 2016;7(45):72593-72607.

Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat Genet. 2016;48(12):1490-1499.

Staunton L, Tonry C, Lis R, Finn S, Leary JO, Loda M, et al. Profiling the tumor microenvironment proteome in prostate cancer using laser capture microdissection coupled to LC⿿MS⿿A technical report. EuPA Open Proteom. 2016;10:19-23.

Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, et al. Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Res Treat. 2016;156(2):405-6.

Evans JR, Zhao SG, S Chang L, Tomlins SA, Erho N, Sboner A, et al. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. JAMA Oncol. 2016;2(4):471-80.

Magro CM, Momtahen S, Lee BA, Swanson DL, Pavlovic MD. Epidermotropic B-Cell Lymphoma: A Unique Subset of CXCR3-Positive Marginal Zone Lymphoma. Am J Dermatopathol. 2016;38(2):105-12.